TY - JOUR A2 - Allegrucci, Cinzia AU - Liu, Jun AU - Lu, Jianjun AU - Li，PY -第2021 - DA - 2021/06/03 TI的全面的预后和免疫分析新Three-Gene签名在肝细胞癌SP - 5546032六世- 2021 AB -很少有报告基因的作用与mRNA相关表达式的具备干细胞预后指数(mRNAsi)和肝细胞的免疫调节癌(HCC)。本研究旨在分析一种新的基于mrna的三基因标记在HCC中的表达谱和预后意义。这三个基因特征是通过分析来自癌症基因组图谱(TCGA) HCC数据集的mrna数据确定的。基于三基因特征的风险评分通过Cox回归和Kaplan-Meier分析评估其预后价值，并在国际癌症基因组联盟(ICGC)数据库中进行验证。同时，分别探讨了风险评分与免疫细胞浸润模式、微卫星不稳定性(MSI)、肿瘤突变负担(TMB)、免疫检查点分子、缺氧相关基因、免疫治疗反应和靶向基因标记化合物的相关性。结果表明，与正常肝组织相比，HCC组织的mRNAsi评分明显升高。在HCC组织中，PTDSS2、MRPL9和SOCS是与mRNAsi最相关的基因。生存分析结果表明，基于三基因标记的风险评分是肝癌患者预后的独立预测指标。 The nomogram combining the risk score and pathological stage showed a good predictive ability for the overall survival of patients with HCC patients. Meanwhile, the risk score was significantly related to immune cell infiltration patterns, MSI, TMB, several immune checkpoint molecules, and hypoxia-related genes. In addition, the risk score was associated with the immunotherapy response, and fifteen potential therapeutic drugs targeting the three-gene signature were identified. Therefore, we propose to use this three-gene signature including PTDSS2, MRPL9, and SOCS as a potential prognostic biomarker for HCC. SN - 1687-966X UR - https://doi.org/10.1155/2021/5546032 DO - 10.1155/2021/5546032 JF - Stem Cells International PB - Hindawi KW - ER -